Cardiovascular disease, coronary artery disease (CAD). Atherosclerotic heart disease of native coronary artery with unstable angina pectoris
Conditions
Interventions
Intervention 1: Intervention group: 1. In this group of study, each patient receives one capsule of 30 mg saffron aqua-extract (made by Dr. Bathaie Lab. Tarbiat Modares University, Faculty of clinical
Sponsors
Vice Chancellor for research of Tarbiat Modares University, Faculty of Medical Science.
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: subjects with coronary artery disease 40-65 years old overweight and obese (BMI 25-35 kg/m2) subjects without a history of myocardial infarction (MI) No tobacco or alcohol consumption who had no symptoms of cancer, auto-immune, allergy, infection, kidney and liver diseases Not consuming of antioxidants supplement and vitamins for the last six months. Signing up the informed consent form
Exclusion criteria
Exclusion criteria: Cardiac events Gestation or Menopause Recent taking systemic medication (other than the usual drug for hypertension, dyslipidemia, and hyperglycemia)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LOX-1 gene relative expression in PBMCs. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: Real time PCR.;MiRNA-223 copy number in PBMCs. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: Real time PCR.;Plasma Homocystein concentration. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: ELISA.;Plasma Proteome patern. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: 2-D Gel Electrophoresis.;Serum concentrations of h-FABP. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: ELISA.;Serum concentrations of MCP-1. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: ELISA.;Serum concentrations of ICAM-1. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: ELISA.;Serum concentrations of VCAM-1. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: ELISA.;Fasting blood glucose (FBG). Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: colorimetric based kit.;Lipid profile. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: colorimetric based kit.;NF?B gene relative expression in PBMCs. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: Real time PCR.;SIRT-1 gene relative expression in PBMCs. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: Real time PCR.;MCP-1 gene relative expression in PBMCs. Timepoint: Before the intervention (day 0), and 8 weeks after t | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index (BMI). Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: height and weight measurement and calculate with formula.;Waist to hip circumference (WHR). Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: spring-loaded tape measure.;Quality of life assessment. Timepoint: Before the intervention (day 0), and 8 weeks after the intervention (day 60). Method of measurement: Mac new quality of life questionnaire for ischemic heart patients. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSaeed Abedimanesh
Tarbiat Modares University
Outcome results
None listed